ASCO 2013: Highlights in Multiple Myeloma
Release Date: June 19, 2013
Expiration Date: June 19, 2014
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
With an estimated 22,350 new cases of multiple myeloma and 10,710 deaths anticipated in the United States in 2013, multiple myeloma remains a challenging and currently incurable disease. Nevertheless, significant progress has been made in prolonging the survival of patients with multiple myeloma in the past decade through rapid advances in clinical research, and consequently it is transitioning to one more characteristic of a chronic disease. As a small population cancer, community oncology physicians and their multidisciplinary care team members, including oncology nurses and pharmacists, may have little real practice experience in managing this malignancy, so it becomes even more essential that community practitioners remain current with the most recent advances in diagnosis, monitoring, and treatment of multiple myeloma. However, busy community practitioners rarely have the time to attend large national meetings where clinical research findings are presented and interpreted as to their impact on practice. This activity is designed to provide highlights of the most promising multiple myeloma clinical studies presented at the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago (May 31-June 3 2013) with interpretation as to their potential impact on practice today and in the near future.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in the treatment of patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Recognize recent clinical findings regarding the monitoring and treatment of multiple myeloma including relevant efficacy, safety and/or trial limitations.
- Relate how these clinical trial findings may impact current or future practice.
Noopur Raje, MD (Moderator) – ASCO 2013: Highlights in Multiple Myeloma
Treatment Goals and Approaches in Monitoring Minimal Residual Disease (MRD) and Newly Approved and Emerging Novel Agents and Immunotherapies for Multiple Myeloma – Kenneth Anderson, MD
The Role of Transplant, Consolidation, and Maintenance Therapy in the Era of Expanding Novel Therapeutic Options – Sergio Giralt, MD
Advances in High-risk Smoldering Myeloma, Minimal Residual Disease Detection, Emerging Monoclonal Antibody-based Therapies, and Emerging Oral Formulation Proteasome Inhibitors – Sagar Lonial, MD
Update on the Initial Therapy of Multiple Myeloma – Donna Reece, MD
Instructions for Participation and Credit
This activity is eligible for credit through June 19, 2014. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Noopur Raje, MD
Director, Multiple Myeloma Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University, India. She has trained in internal medicine at Massachusetts General Hospital (MGH) and has completed a fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute, Boston. Dr. Raje has a joint faculty appointment at MGH and Dana-Farber Cancer Institute. She is an associate professor of medicine at Harvard Medical School and is the director of the Multiple Myeloma Program, Medical Oncology, at MGH. As a hematologist/oncologist at MGH, Dr. Raje's primary focus is in multiple myeloma and related research. Her laboratory focuses on bone biology and the development of novel therapeutics for multiple myeloma, as well as identifying and validating novel targets and translating them into clinical trials.
Dr. Raje is a member of the American Medical Association, America Society of Hematology, American Society of Clinical Oncology, and American Association of Cancer Research, she is also an ad hoc reviewer for several journals including Blood, Clinical Cancer Research, Leukemia, and the American Journal of Hematology. Dr. Raje is the recipient of several awards and has published extensively in the field of multiple myeloma research. Her hope is to continue pursing laboratory and clinical research in the area of multiple myeloma with the goal of translating her efforts to the improvement of patients' lives.
Sergio A. Giralt, MD
Chief, Attending Physician
Adult Bone Marrow Transplant Service
Memorial Sloan-Kettering Cancer Center
New York, New York
Dr. Sergio Giralt received his medical degree from Universidad Central de Venezuela and completed his postgraduate internship at the University Hospital of Caracas. He also completed an internal medicine residency at Good Samaritan Hospital in Cincinnati, Ohio, and a postdoctoral fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center. Dr. Giralt is currently professor of medicine at Weill Cornell College of Medicine and the chief of the Adult Bone Marrow Transplant Service in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City.
Board certified in internal medicine, hematology, and medical oncology, Dr. Giralt holds memberships in several professional societies, including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the North American Society of Blood and Bone Marrow Transplantation, among others. He is a highly sought speaker, lecturer, and presenter who has published hundreds of research articles and abstracts in peer-reviewed literature. Additionally, he is an editorial reviewer for several journals including Blood, Bone Marrow Transplantation, Clinical Cancer Research, Journal of Clinical Oncology, and The Oncologist.
Dr. Giralt's research focus is on stem cell transplantation for patients with blood disorders and improving treatments for older patients who have acute and chronic leukemia. The development of these less intense and less toxic regimens has changed the standard of care for older patients throughout the world.
Kenneth C. Anderson, MD
Kraft Family Professor of Medicine Harvard Medical School
Chief, Division of Hematologic Neoplasia
Director, Jerome Lipper Multiple Myeloma Center
Director, LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Dr. Kenneth Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. He is the Kraft Family Professor of Medicine at Harvard Medical School; and serves as chief of the Division of Hematologic Neoplasia, director of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute.
Dr. Anderson serves as chair of the NCCN Multiple Myeloma Clinical Practice Guidelines Committee; as a Cancer and Leukemia Group B Principal Investigator; on the Board of Scientific Advisors of the International Myeloma Foundation; and is on the Board of Directors and Chair of both the Scientific Advisory Board of the Multiple Myeloma Research Foundation and the Steering Committee of the Multiple Myeloma Research Consortium. Dr. Anderson has published more than 350 original articles, 250 chapters, has edited multiple textbooks on both multiple myeloma and on transfusion medicine, and was named editor in chief of Clinical Cancer Research. In addition, he is a Doris Duke Distinguished Clinical Research Scientist and has received numerous other awards.
Over the last two decades, Dr. Anderson has focused his translational research studies on B-cell malignancies, especially multiple myeloma. His team led both preclinical and clinical trials of the novel proteasome inhibitor bortezomib, as well as lenalidomide. His research offers great promise to improve patient outcome in hematologic malignancies and solid tumors.
Donna Reece, MD
Director, Program for Multiple Myeloma and Related Diseases
Department of Medical Oncology and Hematology
Princess Margaret Hospital
University of Toronto
Dr. Donna Reece received her medical degree from Baylor College of Medicine, Houston, Texas. She completed an internship in internal medicine at the University of Colorado Affiliated Hospitals, a residency and chief residency in internal medicine at Jewish Hospital, St. Louis, and a fellowship in hematology/oncology at Barnes Hospital, Washington University, St. Louis. She was a fellow and later a leukemia/stem cell transplant physician at Vancouver General Hospital/University of British Columbia. Currently, Dr. Reece is associate professor and director of the Program for Multiple Myeloma and Related Diseases in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University of Toronto.
Dr. Reece has served as director of the Outpatient Leukemia/Stem Cell Transplant Program and interim director of the Blood and Marrow Transplant Program of the Markey Cancer Center at the University of Kentucky, Lexington. She is currently chair of the Multiple Myeloma Clinical Trials Group of the National Cancer Institute of Canada, co-chair of the Myeloma Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), as well as a member of the Scientific Advisory Board of the International Myeloma Foundation and the Project Review Committee of the MMRC (Multiple Myeloma Research Consortium). Her career focus has been in the areas of hematopoietic stem cell transplantation, lymphoid malignancies, and plasma cell dyscrasias. She has published numerous articles in these areas.
Sagar Lonial, MD
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Dr. Sagar Lonial received his medical degree from University of Louisville School of Medicine in Kentucky. He completed his hematology-oncology training at Emory University, Atlanta, Georgia, and prior to that received his internal medicine residency at the Baylor College of Medicine in Houston, Texas. Dr. Lonial is currently professor and vice chair of clinical affairs in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine in Atlanta, Georgia.
Board certified in hematology and oncology, Dr. Lonial is also a diplomat of the National Board of Medical Examiners. He is on the editorial board of the American Journal of Clinical Oncology and associate editor of Clinical Lymphoma and Myeloma, and is an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, and Haematologica, among others. In addition, Dr. Lonial has authored or co-authored over 100 papers and abstracts.
Dr. Lonial has worked in the field of immunotherapy and cancer since his arrival at Emory, and has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. Most recently, he has focused on combinations of novel agents as therapy for myeloma and lymphoma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-13-357-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 13-357-321
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made
Dr. Noopur Raje has received honoraria related to formal advisory activities from Celgene Corporation, Millennium: The Takeda Oncology Company, and Onyx. She has received grant support related to research activities from Acetylon Pharmaceuticals, Inc., Amgen Inc., and Eli Lilly and Company.
Dr. Kenneth Anderson has received honoraria related to formal advisory activities from Celgene Corporation, Gilead, Onyx, and sanofi-aventis U.S. LLC. He is the scientific founder of Acetylon Pharmaceuticals, Inc. and OncoPep.
Dr. Sergio Giralt has received honoraria related to formal advisory activities from Celgene Corporation, Onyx Pharmaceuticals, Seattle Genetics, Inc., and Skyline Diagnostics B.V., as well as speakers' bureau activities from Celgene. He received consultant fees from Biokine Therapeutics Ltd., Celgene, Miltenyi Biotec, Onyx, Sanofi and Seattle Genetics.
Dr. Sagar Lonial has received honoraria as a consultant from Bristol-Myers Squibb, Celgene Corporation, Millennium Pharmaceuticals, Inc., Novartis AG, and Onyx.
Dr. Donna Reece has received honoraria related to formal advisory activities from Celgene Corporation, Onyx, and Janssen Pharmaceuticals, Inc., as well as speakers' bureau activities from Janssen, Celgene, and Novartis AG. She has received grant support related to research activities from Bristol-Myers Squibb, Celgene, Merck & Co., Inc., Millennium: The Takeda Oncology Company, and Otsuka Pharmaceutical Co., Ltd.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Drs. Anderson, Giralt, Lonial, and Reece have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Raje has indicated that she does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Drs. Lonial and Reece have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Drs. Anderson, Giralt, and Raje have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Millennium: The Takeda Oncology Company and Celgene Corporation
©2013 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.